CohBar
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1455 Adams Dr Menlo Business Park Ste 20...Phone Number
(650) 446-7888Website
www.cohbar.comRevenue
$13.1 MillionStock Symbol
CWBRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body. CohBar's efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases associated with the underlying impact of mitochondrial dysfunction. The company's lead compound, CB4211, recently completed a Phase 1a/1b clinical trial for nonalcoholic steatohepatitis (NASH) and obesity. In addition, CohBar has four preclinical programs with the most advanced being CB5138-3 for idiopathic pulmonary fibrosis (IPF) and otherRead more
CohBar Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CohBar your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if CohBar had a recent Job posting/layoffs
Funding: Get notified immidiatlly once CohBar has new funding data
Congratulate Masked Content for being promoted to Masked Content at CohBar
Earning: See what the market has to say on CohBar recently announced quarterly report
Product Launch: Get notified when CohBar launches new products
Website visits: Recent activity has been detected on your website
Check if CohBar has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
CohBar, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if CohBar is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to CohBar
Compare insights from companies similar to CohBar, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CohBar is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CohBar is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CohBar.
CohBar financials insights
Gather financial insights about CohBar, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$11.3M
CohBar Tech Stack
A closer look at the technologies used by CohBar
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
New Hire
Executive Move
New Hire
Executive Move
CohBar News & Media
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules testedMorphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) AnnuaLongevity investment bulletin: CohBar, Heartseed, Juvenescence and more
Longevity investment bulletin, featuring CohBar, Heartseed, Juvenescence, Celularity, Hevolution, Samsara and more.SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CohBar, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - May 25, 2023) - Rigrodsky Law, P.A. is investigating CohBar, Inc. ("CohBar") (NASDAQ: CWBR) regarding possible breaches of fiduciary duties and other violations of law related to CohBar's agreement to merge with Morphogenesis, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cohbar-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or email info@rl-legal.com.Rigrodsky...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding CohBar
Sign Up For FreeTo access detailed company insights
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases. Mitochondria based therapeutics originate from the discovery by CohBar's founders of a novel group of naturally occurring peptid... Read More
